NEW YORK, Oct. 16 - Orchid Biosciences has withdrawn a proposed follow-on public offering of over 21/2 million shares of new stock, the Princeton, N.J. company announced Monday.

The manufacturer of SNP scoring technology filed the follow-on public offering with the Securities and Exchange Commission September 22. The total offering was valued at $126,143,500, according to the filing, and included a total of 4,025,000 shares of common stock: the 2 1/2 million new shares, one million existing shares, and additional " green shoe" shares.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.